Takeda Pharmaceutical Co. Ltd. · TSE:4502

Takeda Pharmaceutical — Investor Presentation (September 2018)

13 slides from Takeda Pharmaceutical's investor presentation, September 2018

  1. Slide 1: Takeda Gastroenterology: A Global Leader in Gastroenterology

    TAKEDA GASTROENTEROLOGY A GLOBAL LEADER IN GASTROENTEROLOGY ASIT PARIKH MD, PHD Head, Gastrointestinal Therapeutic Area

  2. Slide 2: We Are a Leading GI Company

    WE ARE A LEADING GI COMPANY GASTROENTEROLOGY OUR VISION Restore Life to Living for patients suffering with GI and liver diseases OUR MISSION Deliver innovative, life-changing therapeutics for patients with GI and liver diseases 2

  3. Slide 3: Our Strategy Expands the Portfolio Across Core Disease Areas Supported by Platform Technologies

    OUR STRATEGY EXPANDS THE PORTFOLIO ACROSS CORE DISEASE AREAS SUPPORTED BY PLATFORM TECHNOLOGIES IBD Celiac disease • Build upon success of Entyvio with new formulations • Advance approaches for the prevention • Expand treatment options with Alofisel of immune responses to gluten Motility disorders L

  4. Slide 4: Executing on Our Strategy Through a Rich, Diversified Pipeline Fueled by Strong External Partnerships

    WE ARE EXECUTING ON OUR STRATEGY THROUGH A RICH, DIVERSIFIED PIPELINE FUELED BY STRONG EXTERNAL PARTNERSHIPS Discovery/preclinical* Phase 1 Phase 2 Phase 3 Approval** Multiple targets in IBD ENTYVIO SC ENTYVIO Needle-free UC/CD, JP, China Multiple targets SC UC/CD Small molecule GvHD prophylaxis IBD

  5. Slide 5: Building on the Success of Entyvio to Address Continued Unmet Need in IBD Patients

    WE ARE BUILDING ON THE SUCCESS OF ENTYVIO TO ADDRESS CONTINUED UNMET NEED IN IBD PATIENTS 1 Geographic expansion 2 First and only biologic specifically targeting gut inflammation New formulations 3 Expanded patient populations 4 New evidence generation First-in-class mesenchymal stem cell therapy fo

  6. Slide 6: Continuously Improving the Value of Entyvio for Patients

    WE ARE CONTINUOUSLY IMPROVING THE VALUE OF ENTYVIO FOR PATIENTS GEOGRAPHIC EXPANDED PATIENT NEW FORMULATIONS EXPANSION POPULATIONS • Japan NDA approval for UC ENTYVIO SUBCUTANEOUS • GvHD prophylaxis Ph3 first patient expected • Potential China approval in FY2020* • Positive topline results from VISI

  7. Slide 7: Entyvio Continues to Deliver Against Unmet Need for Patients

    ENTYVIO CONTINUES TO DELIVER AGAINST UNMET NEED FOR PATIENTS NEW EVIDENCE GENERATION MUCOSAL HEALING IN CROHN’S DISEASE – PREVIOUSLY A GAP FOR ENTYVIO OTHER DATA Complete mucosal healing (absence of ulceration) • Head-to-head vs. adalimumab readout 30% 24% All expected in H1 FY2019 Anti-TNFα naïve •

  8. Slide 8: Alofisel: First and Only Approved (EU) Mesenchymal Stem Cell Therapy for Fistulizing Crohn's Disease

    ALOFISEL: FIRST AND ONLY APPROVED (EU) MESENCHYMAL STEM CELL THERAPY FOR FISTULIZING CROHN’S DISEASE ADDRESSES THE HIGHEST UNMET NEED CX601 MEANINGFULLY IMPROVES STANDARD OF IN IBD, PERIANAL CROHN’S CARE IN ACHIEVING REMISSION (52 WK)* 56.30% 59.20% • ~5% of Crohn’s patients experience perianal fist

  9. Slide 9: TAK-906: Distinctive Mechanism of Action That Fills a Large Unmet Need in Gastroparesis

    TAK-906: DISTINCTIVE MECHANISM OF ACTION (ORAL D2/D3 RECEPTOR ANTAGONIST) THAT FILLS A LARGE UNMET NEED IN GASTROPARESIS CURRENT THERAPIES DO NOT MEET THE TAK-906: PHASE 2A STUDY DEMONSTRATES TARGET SIGNIFICANT UNMET NEED IN GASTROPARESIS ENGAGEMENT AND ENABLES DOSE SELECTION 200 Prolactin concentra

  10. Slide 10: Kuma062: A Highly Potent Oral Glutenase for Celiac Disease

    KUMA062: A HIGHLY POTENT ORAL GLUTENASE THAT COULD CHANGE THE STANDARD OF CARE IN CELIAC DISEASE CELIAC DISEASE GLUTEN RECOVERY FROM RAT STOMACHS 30MINS AFTER DIGESTION OF A HIGH-GLUTEN BREAD SLURRY • Affects ~1% of the population1, rising prevalence 100 • Triggered by exposure to omnipresent gluten

  11. Slide 11: Strengthened Commitment to Liver Diseases Through Early Research Partnerships

    WE HAVE STRENGTHENED OUR COMMITMENT TO ADDRESSING LIVER DISEASES THROUGH EARLY RESEARCH PARTNERSHIPS TARGETING LIVER FIBROSIS PREVENTION AND REVERSAL THROUGH NEW PLATFORMS, NEW PROJECTS AND BUSINESS DEVELOPMENT FOCUSED ON PERI-IND OPPORTUNITIES Human cell system for new Liver-targeted delivery of Ta

  12. Slide 12: Expected Key GI Portfolio Inflections and Milestones

    EXPECTED KEY GI PORTFOLIO INFLECTIONS AND MILESTONES Dates in fiscal year (FY) starting April 1st ENTYVIO (SC UC and SC CD) ENTYVIO EU FILING (IV CD) ENTYVIO ENTYVIO Alofisel JAPAN LAUNCH ENTYVIO (SC CD) (SC UC) (Perianal Crohn’s) (SC UC) US FILING US FILING TIMP-GLIA US Ph3 FSI JAPAN FILING Entyvio

  13. Slide 13: Conclusion

    CONCLUSION 1 Maximizing the potential of ENTYVIO 2 Progressing several early to mid-stage assets 3 Continuing to capture opportunities early and delivering including TAK-906 for through industry-leading ALOFISEL to global gastroparesis and scientific talent, markets KUMA062 for celiac sophisticated

Takeda Pharmaceutical Company — Investor Presentation (September 2018) on 6ix